For example, in advanced prostate and ovarian cancer, the roles of prostate-specific antigen (PSA) and CA125, respectively, in predicting response to treatment and survival outcome have been clearly established and these markers are used routinely in clinical practice to monitor the effects of therapy [6]. This evidence concerns the gene KLK3 and ovarian cancer.